The use of for first-line immunotherapy for advanced GC, HER2- patients can choose Nivolumab or Sintilimab combined with chemotherapy, and HER2 + patients are recommended to be treated with Trastuzumab combined with Pembrolizumab combined with chemotherapy. This evidence concerns the gene ERBB2 and gastric cancer.